Active, not recruitingPhase 2NCT02101775
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Studying Primary peritoneal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Amit M Oza, MDUniversity Health Network-Princess Margaret Hospital
- Intervention
- Adavosertib(drug)
- Enrollment
- 124 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2014 – 2027
Study locations (16)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- City of Hope South Pasadena, South Pasadena, California, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- Decatur Memorial Hospital, Decatur, Illinois, United States
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
- BCCA-Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
- BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada
- London Regional Cancer Program, London, Ontario, Canada
- Ottawa Hospital and Cancer Center-General Campus, Ottawa, Ontario, Canada
- University Health Network Princess Margaret Cancer Center P2C, Toronto, Ontario, Canada
- University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
- CHUM - Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02101775 on ClinicalTrials.govOther trials for Primary peritoneal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07480954Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07322094CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian CancerTORL Biotherapeutics, LLC
- RECRUITINGPHASE3NCT06915025Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerImunon
- RECRUITINGPHASE2NCT07023484Personalized Timing of Interval Debulking Surgery in Advanced Ovarian CancerThe University of Hong Kong
- RECRUITINGPHASE2NCT06639074Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT TrialMayo Clinic
- RECRUITINGPHASE1NCT06469281A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRegeneron Pharmaceuticals
- RECRUITINGPHASE2NCT06492070Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological CancersEmory University
- RECRUITINGPHASE2NCT06434610A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.Shanghai Jiaolian Drug Research and Development Co., Ltd